Clinical Trials Directory

Trials / Completed

CompletedNCT00247819

The Genetic Basis for Vulnerability to Substance Abuse

Allelic Linkage in Substance Abuse

Status
Completed
Phase
Study type
Observational
Enrollment
8,000 (estimated)
Sponsor
National Institute on Drug Abuse (NIDA) · NIH
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

This investigation seeks to better define the genetic basis for vulnerability to substance abuse.

Detailed description

Dopamine (DA), a neurotransmitter helping to mediate reward and reinforcement, has been putatively linked to the development of substance abuse, alcohol abuse, and alcoholism. Identification of specific vulnerability-association alleles for receptors, other molecules within the reward mediating system, and other genes that may predispose individuals to the development of such disorders is the goal of the study. This investigation will help elucidate the genetic underpinnings of substance abuse, potentially leading to the improved methods to diagnose those at risk and to help develop better therapeutic interventions.

Conditions

Interventions

TypeNameDescription
PROCEDUREBlood draw

Timeline

Start date
1992-08-01
Primary completion
2006-02-01
Completion
2006-02-01
First posted
2005-11-02
Last updated
2017-01-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00247819. Inclusion in this directory is not an endorsement.

The Genetic Basis for Vulnerability to Substance Abuse (NCT00247819) · Clinical Trials Directory